Elliot Norry, MD on ADP-A2M4 Synovial Sarcoma and MRCLS Patient Enrollment

Elliot Norry, MD on ADP-A2M4 Synovial Sarcoma and MRCLS Patient Enrollment

Cancer-News

6 days
5 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Elliot Norry, MD of Adaptimmune Therapeutics discusses the SPEARHEAD-1 trial with ADP-A2M4 for people with synovial sarcoma and myxoid/round cell liposarcoma (MRCLS). Adaptimmune’s ADP-A2M4 was granted ODD by the FDA late last year for soft tissue sarcomas and Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of synovial sarcoma.

Read here: https://www.globenewswire.com/news-release/2020/04/28/2023245/0/en/Positive-Opinion-for-Orphan-Drug-Designation-for-ADP-A2M4-in-the-European-Union-for-the-Treatment-of-Soft-Tissue-Sarcoma-from-EMA-Committee-of-Orphan-Medicinal-Products.html

Up Next Autoplay